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Abstract
Background: Serological study of human papillomavirus (HPV)-antibodies in order to estimate
the HPV-prevalence as risk factor for the development of HPV-associated malignancies in human
immunodeficiency virus (HIV)-positive men.
Methods:  Sera from 168 HIV-positive men and 330 HIV-negative individuals (including 198
controls) were tested using a direct HPV-ELISA specific to HPV-6, -11, -16, -18, -31 and bovine PV-
1 L1-virus-like particles. Serological results were correlated with the presence of HPV-associated
lesions, the history of other sexually transmitted diseases (STD) and HIV classification groups.
Results:  In HIV-negative men low risk HPV-antibodies were prevailing and associated with
condylomatous warts (25.4%). Strikingly, HIV-positive men were more likely to have antibodies to
the high-risk HPV types -16, -18, -31, and low risk antibodies were not increased in a comparable
range. Even those HIV-positive heterosexual individuals without any HPV-associated lesions
exhibited preferentially antibody responses to the oncogenic HPV-types (cumulative 31.1%). The
highest antibody detection rate (88,8%) was observed within the subgroup of nine HIV-positive
homosexual men with anogenital warts. Three HIV-positive patients had HPV-associated
carcinomas, in all of them HPV-16 antibodies were detected. Drug use and mean CD4-cell counts
on the day of serologic testing had no influence on HPV-IgG antibody prevalence, as had prior
antiretroviral therapy or clinical category of HIV-disease.
Conclusion: High risk HPV-antibodies in HIV-infected and homosexual men suggest a continuous
exposure to HPV-proteins throughout the course of their HIV infection, reflecting the known
increased risk for anogenital malignancies in these populations. The extensive increase of high risk
antibodies (compared to low risk antibodies) in HIV-positive patients cannot be explained by
differences in exposure history alone, but suggests defects of the immunological control of
oncogenic HPV-types. HPV-serology is economic and can detect past or present HPV-infection,
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independently of an anatomical region. Therefore HPV-serology could help to better understand
the natural history of anogenital HPV-infection in HIV-positive men in the era of antiretroviral
therapy.
Background
Venereal diseases, sexual promiscuity and receptive anal
intercourse are associated with an increased risk for anal
cancer. Particularly, in HIV-infected individuals an alarm-
ing increase of HPV-associated malignancies has to be ex-
pected [1–3]. Recent data from the US AIDS-cancer
registry reveal for women and men with HIV-infection 6.8
and 37 times greater relative risks for anal cancer com-
pared to respective control populations. It appears, that
potent antiretroviral therapy has limited effect in inducing
regression of HPV-lesions and HPV-DNA tends to persist
in the anorectal canal [4]. Progression from high-grade sq-
uamous intraepithelial lesions (HSIL) to cancer may take
as long as 10 or more years in HIV-seronegative individu-
als. Therefore it is hypothesised, that in the era of antiret-
roviral therapy the incidence of anogenital cancer in HIV-
positive patients will increase as consequence of prolong-
ing survival combined with persistent deviations of the
immune system.
A breakthrough in the prophylaxis of cervical cancer has
been achieved by introduction of cervical cytological test-
ing described in the report of Papanicolaou and Trout [5].
A 53% reduction in cervical cancer mortality was reported
in Sweden [6]. and Quinn estimated 1997 that without
screening there might have been 800 more deaths in Eng-
land from cervical cancer in women under 55 years of age
[7]. Nowadays, high risk lesions could also be identified
by detecting viral HPV-DNA in cervical smears [8].
The incidence of anal cancer in HIV-positive men will be
probably higher than the incidence of cervical cancer prior
the use of cervical cytology screening [9]. However, even
in risk groups – such as HIV-positive homosexual men –
there are no such standard screening and management
procedures established for the anus. Routine cytological
screening has to await an effective proved intervention for
anal intraepithelial neoplasia [10]. Antibodies to HPV
capsid antigens are reliable markers for cumulative HPV
exposure and have been used in prospective studies, that
linked HPV infection to cancers [11]. Therefore we inves-
tigated HPV-antibodies in order to estimate the HPV-prev-
alence as risk factor for the development of HPV-
associated malignancies, particularly, in HIV-positive
men.
Methods
HIV-positive patients
The AIDS clinic at the University of Innsbruck is the only
centre for patients with HIV/AIDS of the Austrian Tyrol.
More than 95% of the Tyrolean AIDS-patients with AIDS
reported to the health authorities are in treatment at this
clinic. One hundred and sixty-eight HIV-positive men
(aged 23 to 61 years, median 43) were regularly seen at
our department and sera from the year 1998 were availa-
ble from all of the patients. Fifty-nine were homosexuals
(35.1%), previous or present intravenous drug use was
known from 60 men (35,7%) and blood products were
the source of HIV-infection in 8 men (4,7%). The remain-
ing 41 men (24.5%) were infected by heterosexual con-
tacts or the transmission route was unknown.
The CD4-cell counts at the time of serum collection were:
42 patients <200/µl, 61 patients 200–400/µl, 65 patients
>400/µl. Sixty (35.8%) patients were according to the
classification of the Centre of Disease Control (CDC) in
asymptomatic disease stage CDC A, fifty-four (32.1%) in
mild symptomatic CDC B and fifty-four (32.1%) in CDC
C. Stage CDC C is equivalent to AIDS. Antiretroviral ther-
apy at the time of serum collection (1998) was already in-
itiated in 96 (57.1%) individuals. HPV-associated
diseases in HIV-positive men were present in 28 (16.6%)
patients: 25 (14.8%) men had condylomatous warts and
3 (1.7%) invasive carcinomas (2 anal and 1 rectal squa-
mous cell carcinoma). Two of this 3 carcinoma patients
were homosexuals. History for other sexually transmitted
diseases (STD) was positive in 42 (25%) men, being treat-
ed for genital herpes, gonorrhoea, clamydia or syphilis.
HIV-negative patients with HPV lesions
HIV-negative individuals with HPV-associated diseases
studied were 55 men with condylomatous genital warts
and 7 men with genitoanal cancer. An additional group
consisted of 70 nonpregnant HIV-negative women with
external condylomatous warts but normal pap smears, in
order to allow comparison of seroresponses in women
and men.
Control patients
There were two groups of male HIV-negative patients as
follows: First, 98 heterosexual men randomly chosen
from patients visiting the dermatological outpatient clinic
representing a cross-section of men attending a university
hospital in Austria, with no bias as to social or economic
status. The reasons for consulting the clinic were skinBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/6
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disorders (e.g. eczema, psoriasis). Patients with drug
abuse, homosexuality, malignancies, existing or previous
HPV-related diseases or other STD were excluded (ques-
tionnaire). The second control group consisted of 100
blood donors being routinely screened for infectious dis-
eases or immune activation (serum neopterin level) but
without available information concerning genital warts or
sexual behaviour.
The age of all 260 HIV-negative men (median age 42,5
years) did not differ significantly compared with the HIV-
positive patients.
HIV-serology and sampling
Sera were screened for HIV antibodies using the Enzyg-
nost Anti HIV 1/2 ELISA (Behring, Germany) and con-
firmed by Western Blot (Du Pont de Nemours, Germany,
or Biotechnologies, Singapore) in at least two different
samples. Serum samples for HPV analysis obtained from
all individuals were frozen, preserved at -80°C and used
for later HPV serology.
HPV-ELISA
Baculovirus-expressed HPV-6, -11, -16, -18, -31 and BPV-
1 L1-virus-like particles (VLPs) were used as antigens in di-
rect ELISAs as described previously [12]. Briefly, VLPs
1:100 diluted in PBS were attached to wells of round bot-
tom ELISA plates (Nunc™ Brand Products and Petra Plas-
tic 96 rounded wells γ-sterilized Typ F – ELISA 11041 E)
by incubating 90 µl of VLP-solution/well at room temper-
ature for 45 min. VLP-free PBS-incubated wells were used
as negative control wells. All plates were washed three
times with PBS (SLT Labinstruments 812 SW2) and were
incubated with 200 µl milk-buffer (1 g Fixmilch Instant®
+ 20 ml Dulbecco's® phosphate buffered saline) / well for
30 min (room temperature). Patient sera were heat-inacti-
vated at 56°C for 30 min and used at a final serum dilu-
tion of 1:100. Each patient's serum (25 µl) and positive
and negative controls were tested in duplicate wells and
incubated for 1 h and washed again three times. Mono-
clonal antibodies (100 µl) corresponding to VLP-types
(positive control wells) were diluted with 5% milk-PBS
(final dilution of 1:200). Subsequently the wells were in-
cubated with goat anti-human IgG (1:10000), and RαM
(1:1000) antibodies (Sigma, St. Louis). After incubation
for 30 min. (room temperature) the wells were washed
three times and substrate (TRIS-puffer with p-Nitrophe-
nylphosphate tablets) was added. Optical densities
(OD's) were read on a microplate reader (SLT Labinstru-
ments 400 ATC, Salzburg, Austria; Software Easy-Fit) at
405 nm 30, 60, and 90 min after adding substrate. Means
and standard deviations (SD) of duplicate wells were cal-
culated as final OD values for each serum sample. There
was a high correlation of paired values and there were
only rarely duplicates which were not consistent with each
other. These tests were repeated. The coefficient of varia-
tion of selected sets of samples for each ELISA experiment
ranged between 0.7 and 4%. In addition in subsets of
more than 100 patient sera reproducibility was at least
94%.
Statistical analysis
In all experiments patient and control sera were analysed
together. Means and SD of ELISA absorbency values of the
control group (dermatology clinic patients) were used sta-
tistically to define positive and negative patient sera for
each target antigen (HPV-6, -11, -16, -18, -31 and bovine
PV-1). Individual values in the control group exceeding
the mean + 3 SD were excluded and the remaining read-
ings were averaged again until no further values exceeded
the recalculated mean + 3 SD. Samples with values greater
than the recalculated final mean + 3 SD were designated
positive for reactivity to the appropriate antigen in the cur-
rent experiment. For scalar variables, the non parametric
Mann-Whitney U test was used for statistical analysis, be-
cause group OD values had an asymmetric distribution;
Fisher's exact test was used for categorical variables. P <
0.05 (two tailed) was considered statistically significant.
All calculations were done with SheePS Counting Soft-
ware (SPSS) 7.0 for Windows 95.
Results
In general, the prevalence of HPV-antibodies was signifi-
cantly lower in men compared to women. Data for HIV-
negative patients with condylomatous warts are shown in
table 1.
Table 1: HPV-capsid antibodies in HIV-negative patients with condylomatous warts (women compared to men)
VLP-type 6 11 16 18 31 cumulative cumulative
low risk (6, 11) high risk (16, 18, 31)
women (n = 70) 47 % 14 % 24 % 10 % 14 % 54 %* 34 %**
men (n = 55) 24 % 7 % 7 % 9 % 5 % 25 %* 13 %**
*p = 0.0018, Odds ratio (95% CI), 0.28 (0.13–0.6); **p = 0.0066, Odds ratio (95% CI), 0.28(0.11–0.671BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/6
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HPV-ELISA; comparison of HIV-positive and HIV-negative 
men
Both HIV-negative male control groups (patients of der-
matological clinic or blood donors) had similar low HPV
antibody rates: Reactivity to HPV-6/ -11 and -16/ -18/ -31
was observed respectively in 10,2% / 5,1% and 5,1% /
5,1% / 6,1% of patients without HPV-lesions (dermatolo-
gy clinic patients). HIV-positive men were significantly
more likely than HIV-negative men to have detectable lev-
els of antibodies in particular to the high-risk VLPs (HPV
types -16, -18, -31). In contrast, low risk antibodies were
only increased to a lesser extend. In 168 HIV-positive men
IgG reactivity to HPV-6/ -11 and -16/ -18/ -31 was ob-
served in 19% / 16% and 27,9% / 19,6% / 20,2%. Overall
seropositivity rates are summarised in table 2. HIV-posi-
tive men with warts were more likely to have high risk
HPV-antibodies (16/25 = 64%) compared to all HIV-pos-
itive men without warts (50/143 = 34%): p = 0.0078,
Odds ratio (95% CI), 3.3 (0.18–0.79). In HIV-negative
men, particularly in those with condylomatous warts,
mainly low risk HPV-antibodies were detected, whereas in
all groups of HIV-positive men high-risk HPV antibody
were more prevalent. In HIV-positive men with benign
genital warts and even in men without any clinical evident
genitoanal lesions the cumulative high risk antibody sero-
prevalence was much higher than expected. This phenom-
enon remained evident analysing the complete cohorts of
patients: The risk for HIV-positive men (n = 168) in com-
parison to HIV-negative men (n = 260) to have detectable
high risk-HPV antibodies was much higher (O.R. = 5.343;
95% CI: 3,27–8.71) than the risk to have HPV-low risk an-
tibodies (O.R. = 2.075; 95% CI: 1.25–3.42). No signifi-
cant reactivities were seen with the bovine PV control
antigen.
HPV-ELISA; analyses within the HIV-positive cohort
Only three HIV-positive patients had HPV-related inva-
sive carcinomas. In all of them HPV-16 antibodies were
Table 2: Seroreactivity in association with benign condylomatous warts: Cumulative antibody responses to low risk (HPV-6, -11) or high 
risk (HPV-16, -18, -31) VLPs in HIV-positive versus HIV-negative men
Men with warts: HIV-positive (n = 25, HIV-negative (n = 55)
including 9 homosexuals)
antibodies to low risk HPV 10 (40 %)+ 14 (25.4 %)+
antibodies to high risk HPV 16 (64 %)* 7 (12.7 %)*
Heterosexuals without warts: HIV-positive (n = 93) HIV-negative (n = 98)
antibodies to low risk HPV 15 (16.1 %) 12 (12.2 %)
antibodies to high risk HPV 29 (31.1 %)** 11 (11.2 %)**
Homosexuals without warts: HIV-positive (n = 50) -
antibodies to low risk HPV 15 (30%) -
antibodies to high risk HPV 21 (42%) -
Male blood donors: - HIV-negative (n = 100, STD history unknown)
antibodies to low risk HPV - 9 (9 %)
antibodies to high risk HPV - 10 (10 %)
In HIV-positive men preferentially the high risk antibody prevalence is increased: + p = 0.2, *p < 0.0001, Odds ratio (95% CI), 12.2 (3.9–38.1); **p = 
0.0007, Odds ratio (95%), 3.6 (1.7–7.7)
Table 3: HPV-capsid antibodies in HIV-positive (+) or HIV-negative (-) men with anogenital carcinoma
V L P - t y p e 6 1 11 61 83 1c u m u l a t i v e c u m u l a t i v e
low risk (6, 11) high risk (16, 18, 31)
HIV + (n = 3) 3/3 2/3 3/3 2/3 2/3 3/3 3/3
HIV - (n = 7) 0/7 0/7 1/7 0/7 1/7 0/7 2/7BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/6
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detected, whereas in 7 HIV-negative men with anal can-
cers only 1 had HPV-16 antibodies. The number of pa-
tients with malignancies was to small for statistical
analysis. Data of cancer patients are shown in table 3.
Clinical detection of warts in HIV-positive patients was as-
sociated with low risk HPV-antibodies (table 2), but sta-
tistics revealed a trend only (p = 0.07). High-risk HPV-IgG
antibodies were detected more frequently despite absence
of anogenital carcinoms: high-risk antibodies were detect-
ed in 16 of 25 HIV-infected men with benign
condylomatous warts (64%) and in 48 of 140 men with-
out warts (34%). The most prevalent antibody in HIV-
positive men was reactive with HPV-16 VLPs and was de-
tected in 20.7 % of 140 men without any HPV-lesions,
reached a percentage of 52% in 25 men with benign con-
dylomatous warts and 100 % in 3 men with anal carcino-
mas. Antibody reactivities to different HPV-types are
shown in table 4. The highest antibody detection rate
(88,8%) was observed with the 3 high-risk HPV-types to-
gether within the subgroup of nine HIV-positive homo-
sexual men with genitoanal warts. Even homosexual men
without HPV-lesions (n = 50) had HPV-antibodies in
50%. Drug users (all of them heterosexuals) were the sub-
group with the lowest HPV-antibody prevalence, al-
though drug abuse is a well-known single risk factor for
STD. Mean CD4-cell counts on the day of serologic testing
had no influence on HPV-IgG antibody prevalence, as had
prior antiretroviral therapy or clinical category of HIV-dis-
ease (table 5).
HPV-ELISA; type specificity and double reactivity
In HIV-positive men Ig reactivity to more than one high-
risk or low-risk HPV-type was found in the range of 30%
of positive sera. Preferentially double reactivity with the
closely related VLP types HPV-6 and -11 were seen
(42,6%). HPV-16 and HPV-18 double reactivity was
detected in 31% and with the types HPV-16 and HPV-6 in
25% only. Double reactivity within the high risk HPV-an-
tibody group appeared to be associated with a history of
other STDs than warts (genital herpes, gonorrhoea, clamy-
dia or syphilis): In 42 HIV-positive men with STDs 7 of 21
(33.3%) HPV-positive sera were HPV-16/18 double reac-
tive; In 126 HIV-positive men without such STDs 11 of 56
(19.6%) Statistics revealed a trend only (p = 0.0539).
Discussion
Among women and men the incidence of anal cancer has
increased in recent decades. Anal cancer is an infectious
disease associated with human papillomavirus (HPV) ex-
posure influenced by the human immunodeficiency virus
(HIV) epidemic [13]. High risk HPV-DNA, which is
known to cause cancer of the cervix, was found in 84% of
anal cancer tissue specimens [14]. The present study dem-
onstrates, that HIV-infected men are able to generate a vig-
Table 4: HPV-capsid antibodies in subgroups of HIV-positive men
VLP-type 6 11 16 18 31 cumulative cumulative
low risk (6, 11) high risk (16, 18, 31)
all men (n = 168) 19% 16% 30% 20% 20% 24% 41%
homosexuals with warts (n = 9) 55% 44% 67% 33% 67% 67% 89%
homosexuals without warts (n = 50) 22% 14% 30% 26% 26% 30% 42%
heterosexuals with warts (n = 16) 19% 19% 44% 19% 12% 25% 50%
heterosexuals without warts (n = 93) 12% 14% 19% 12% 13% 16% 31%
drug users (n = 60) 12% 8% 18% 8% 13% 13% 28%
Table 5: HPV-capsid antibodies in subgroups of HIV-positive men stratified by CD4 counts or high active antiretroviral therapy 
(HAART)
HPV antibodies cumulative low risk (6, 11) cumulative high risk (16, 18, 31)
CD4+ cells <200 /µl (n = 42) 8 (19,0%) 17 (40,4%)
CD4+ cells 200–400/µl (n = 61) 16 (26,2%) 24 (39,3%)
CD4+ cells <200 /µl (n = 65) 16 (24,6%) 25 (38,4%)
with HAART (n = 96) 26 (27,1%) 42 (43,7%)*
without HAART (n = 72) 14 (19,4%) 24 (33,3%)*
*p = 0.2, Odds ratio (95% CI), 1.6 (0.8–2.9)BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/6
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orous anti-HPV serological response against these
infections. This is not surprising since in HIV-positive pa-
tients the humoral immunity is much less impaired com-
pared to cellular immune functions. In addition, HPV has
probably been acquired many years before severe defi-
ciencies of immune functions in AIDS patients develop.
In HIV-positive individuals the seroreactivity rate was
lower in men than in women compared to our recently
published data on IgG reactivity to HPV-6/ -11 and -16/ -
18/ -31 in 19% / 31% and 49% / 30% / 24% in HIV-pos-
itive women, respectively [12]. In this previous study
HPV-seropositivity in HIV-positive women was even high-
er than in 48 HIV-negative women with cervical intraepi-
thelial lesions or cancer exhibiting percentages as follows:
8% / 2% and 31% / 15% / 15%. The phenomenon of low-
er HPV-seroreactivity in men was also seen in the present
study comparing HIV-negative men and women with con-
dylomatous warts. In general, men appear to be less likely
to be HPV-seropositive, despite of exhibiting increased
risk behaviour [15]. Nevertheless, HPV-antibody detec-
tion in men was associated with HPV-associated lesions
and/or HIV-seropositivity. The most striking result was
the observation, that even those HIV-positive individuals
without clinical evident HPV-associated lesions exhibited
antibody responses preferentially to oncogenic HPV-
types, whereas the prevalence of low risk antibodies was
only moderately increased. This observation strongly sug-
gests that – at least in part – immune deviations associated
with HIV rather than differences in exposure history con-
tributed to the observed discrepant low risk and high risk
HPV sero-prevalences in HIV-positive individuals.
The highest HPV-seroprevalence was observed in the sub-
group of homosexual men. This prevalence was in the
range of a previous study on HPV-6 and HPV-16 antibod-
ies in men [16]. In addition, Hagensee et al have shown a
similar seroprevalence in homosexuals with or without
HIV. The phenomenon that high-risk HPV-antibodies are
much more prevalent than low-risk antibodies in HIV-
positive and/or homosexual individuals reflects obviously
the known increased risk for anogenital malignancies in
these populations. It is interesting to note, though, that in
our HIV-negative men high risk HPV-antibodies were not
a reliable marker for anogenital cancer, although the 3
tested high risk HPV types (16, 18, 31) normally comprise
more than 80% of oncogenic HPV-types e.g. detected in
cervical carcinomas in Europe: Only 2 of 7 HIV-negative
cancer patients had these high risk antibodies, whereas in
the small group of 3 HIV-positive cancer patients all had
antibodies. In risk populations a further increase of anal
carcinomas has to be expected in the future, since at the
end of the study in 2002 (including a follow up period of
3–4 years) three HIV-positive men had already HPV-relat-
ed carcinomas. This rate would be equivalent to an inci-
dence of 170 per 100 000.
The rate of antibody double reactivities with more than
one HPV-type was in the range as observed in HIV-posi-
tive women [12], suggesting comparable exposure to var-
ious HPV-types in women and men. Double reactivity
could reflect crossreactivity or infection with multiple
HPV types, but at least in part the data indicate infection
with multiple HPV-types, since we have previously per-
formed competition experiments and analyses with mon-
oclonal mouse antibodies showing, that type specific IgG
antibodies exist, which discriminate even the closely relat-
ed HPV types -6 and -11 [17]. In the present study there
was accordingly a trend for double reactivity in
homosexuals and in HIV-positive men with histories of
STDs suggesting infections with multiple HPV types.
The extraordinary high prevalence of high risk HPV-anti-
bodies exceeding the low risk HPV-antibody prevalence in
HIV-positive individuals needs to be interpreted. HIV-in-
fected individuals are obviously not able to sufficiently
control particularly high risk HPV by cellular immune
mechanisms resulting in prolonged persistence of HPV-
DNA as demonstrated [18]. The occurrence of complete
life cycles of HPV and subsequent capsid expression is
thought to be the primary determinant of a detectable hu-
moral response, reflecting lifetime cumulative exposure to
HPV [19]. Seropositivity is probably a better marker for
past sexual behaviour than presence of HPV-DNA [20].
Therefore, our data suggest that HIV-positive men are
intensely exposed to high-risk HPV proteins throughout
the natural course of their HIV infection. This persistence
of oncogenic HPV-types could be one explanation for the
association of HIV with HPV-associated malignancies. An
interaction of HIV and HPV and local factors are probably
also involved in the carcinogenesis in HIV-positive indi-
viduals [21,22].
Dysplasia may also develop in visually normal anal muco-
sa [23], but routine anal cytology is not established. In ad-
dition, women – despite of the absence of evidence for
cervical disease – may also be at risk for anal disease, in a
region were HPV-screening is usually not performed.
HPV-serology could be used for risk assessment in HIV-
positive patients to circumvent these problems, since se-
rology is convenient, economic and can detect past and
present HPV-infection, independently of an anatomical
region. In HIV-negative women it has been shown, that
HPV-antibodies in prediagnostic sera indicate risk for oc-
currence of cervical cancer: the relative risk was highest
(odds ratio = 7,5) in patients with high antibody levels
[24].BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/6
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Conclusions
We conclude, that the high seroprevalence of HPV-anti-
bodies in HIV-positive men reflects a high lifetime cumu-
lative exposure to oncogenic HPV-types. This may be due
to risky sexual behaviour in combination with defects of
the immunological control of HPV. The serological data
are in line with published results on anal intraepithelial
neoplasia associated with HPV-DNA, which was demon-
strated in 84 % among HIV-positive homosexual men
[25]. A role of HPV-serology for diagnostic strategies in
HIV-infected individuals remains to be determined, but
the presented serological data will be the basis for a close
follow up in the next decade, in order to better understand
the natural history of anogenital HPV-infection in HIV-
positive men in the era of antiretroviral therapy. HIV-in-
fected patients may also be candidates for prophylactic
HPV-vaccination strategies, since in these individuals a
humoral immune response to HPV occurs.
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